コロニー刺激因子(CSF)の臨床

出版社: 日本医学館
著者:
発行日: 2001-12-10
分野: 臨床医学:一般  >  薬物療法
電子書籍版: 2001-11-09 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

7,040 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,520 円(税込)

商品紹介

本書は全3章から構成されており、第1章ではCSFが造血においてどのような役割をもっているか、CSFがどのように発見 純化され、遺伝子クローニングされたか、どのような分子種が存在するか、そしてどのような物理化学的性質及び生物活性をもっているかなど、CSFの基礎知識及びM-CSFに関してこれまで実施された大規模二重盲検群間比較試験からどのような臨床効能が実証されているかをEBMに基づいて解説します。

目次

  • コロニー刺激因子(CSF)の臨床
    元吉和夫・浦部晶夫/編
    《195ページ》

    ―目 次―
    1 コロニー刺激因子(CSF)の基礎知識
    1-1 造血の仕組みとCSF
    1-2 G-CSFの性状
    1-3 M-CSFの性状
    2 顆粒球コロニー刺激因子(G-CSF)
    G-CSFの臨床応用の現況
    2-1 癌化学療法におけるG-CSF
    2-2 造血幹細胞移植におけるG-CSF
    2-3 再生不良性貧血におけるG-CSF
    2-4 骨髄異形成症候群におけるG-CSF
    2-5 G-CSFによる化学療法のプライミング
    2-6 G-CSFによるdose intensityを高めた化学療法
    G-CSFの新しい展開
    2-7 感染症への臨床応用
    2-8 In vitroでの造血幹細胞の増幅
    2-9 遺伝子治療へのアプローチ
    3 マクロファージコロニー刺激因子(M-CSF)
    M-CSFの臨床応用の現況
    3-1 骨髄移植におけるM-CSF
    3-2 急性骨髄性白血病治療におけるM-CSF
    3-3 卵巣癌治療におけるM-CSF
    3-4 M-CSF穿孔投与によるG-CSFの効果増強
    M-CSFの新しい展開
    3-5 M-CSFの骨髄異形成症候群への応用
    3-6 心筋症に対するM-CSF・アンフォテリシン併用療法
    3-7 造血支持細胞とM-CSF
    3-8 M-CSFの癌予後改善効果
    3-9 骨吸収とM-CSF
    3-10 不育症とM-CSF
    3-11 M-CSFによる悪性腫瘍に対する遺伝子治療
    3-12 卵巣癌化学療法時の好中球接着分子の動態

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 コロニー刺激因子 (CSF)の基礎知識

P.12 掲載の参考文献
1) Bradley TR, Metcalf D:The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287-299, 1965.
5) Dexter TM, Allen TD, Lajtha LG et al.:In vitro analysis of self-renewal and commitment of hematopoietic stem cells. Cold Spring Harvor Conferences on Cell Proliferation V5, "Differentiation of normal and neoplastic hematopoietic cells, Book A". (ed. Clarkson B, Markes PA, Till JE), Cold Spring Harbor Laboratory, Cold Spring Harbor, 1982, p 63-79.
7) Tanaka-Douzono M, Suzu S, Yamada M et al.:In Vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells. J Cell Physiol 178:267-273, 1999.
9) Civin CI, Stauss LC, Brovall C et al:Antigenic analysis of hematopiesis III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG1a cells. J Immunol 133:157-165, 1984.
11) Motoyoshi K, Yoshida K, Hatake K et al.:Recombinant and native human urinary colony-stimulating factor directly augments G-and GM-CSF production of human peripheral blood monocytes. Exp Hermatol 17:68-71, 1989.
12) Motoyoshi K, Takaku F:Human monocytic colony-stimulating factor (hM-CSF), phase I/II clinical studies. Hematopoietic Growth Factors in Clinical Applications. (ed. Mertelsmann R, Herman F), Marcel Dekker, Inc., New York, 1991, p 161-175.
13) Hashimoto S, Yoda M, Yamada M et al.:Macrophage colony-stimulating factor induces interleukin-8 production in human monocytes. Exp Hematol 24:123-128, 1996.
15) Hanamura T, Motoyoshi K, Yoshida K et al.:Quantitation and identification of human monocytic colony-stimulating factor in human serum by enzyme-linked immunosorbent assay. Blood 72:886-892, 1988.
21) Matsumoto Y, Aoki K, Yagami Y:Serum macrophage colony-stimulating factor levels in recurrent spontaneous abortion patients. Nagoya Med J 40:29-39, 1995.
P.18 掲載の参考文献
5) Platzer E, Welte K, Gabrilove J, Lu L et al.:Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 162:1788, 1985.
6) Stife A, Lambek C, Wisniewski D et al.:Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells. Blood 69:1508, 1987.
8) Nomura H, Imazaki I, Oheda M et al.:Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J 5:871, 1986.
9) Gabrilove J, Welte K, Lu L et al.:Constitutive production of leukemia differentiation, colony-stimulating, erythroid burst-promoting, and pluripoietic factors by a human hepatoma cell line:characterization of the leukemia differentiation factor. Blood 66:407, 1985.
11) Komatsu Y, Matsumoto T, Kuga T et al.:Cloning of granulocyte colony-stimulating factor cDNA from human macrophages and its expression in Esherichia coli. Jpn J Cancer Res 78:1179, 1987.
12) Le Beau M, Lemons R, Carrino J et al.:Chromosomal localization of the human G-CSF gene to 17q11 proximal to the break point of the t(15;17) in acute promyelocytic leukemia. Leukemia 1:795, 1987.
13) Nagata S, Tsuchiya M, Asano S et al.:The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J 5:575, 1986.
14) Hill CP, Osslund TD, Eisenberg D:The structure of granulocyte colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci USA 90:5167, 1993.
18) Demetri GD, Griffin JD:Granulocyte colony-stimulating factor and its receptor. Blood 78:2791, 1991.
20) Fukunaga R, Ishizaki IE, Nagata S:Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. J Biol Chem 265:14008, 1990.
23) Avalos BR:Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 88:761, 1996.
P.24 掲載の参考文献
1) Stanley ER, Hansen G, Woodcock J et al.:Colony stimulating factor and the regulation of granulopoiesis and macrophage production. Fed Proc 13:2272-2278, 1975.
2) Motoyoshi K, Takaku F, Mizoguchi H et al.:Purification and some properties of colony-stimulating factor from normal human urine. Blood 5:1012-1020, 1978.
6) Morris SW, Valentine MB, Shapiro DN et al.:Reassignment of the human CSF1 gene to chromosome 1 p13-p21. Blood 78:2013-2020, 1991.
7) Ladner MB, Martin GA, Noble JA et al.:Human CSF-1:gene structure and alternative splicing of mRNA precursors. EMBO J 6:2693-2698, 1987.
14) Stein J, Borzillo GV, Rettenmier CW:Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1. Blood 76:1308-1314, 1990.
15) Suzu S, Yanai N, Sato-Somoto Y et al.:Characterization of macrophage colony-stimulating factor in body fluids by immunoblot analysis. Blood 77:2160-2165, 1991.
16) Suzu S, Ohtsuki T, Yanai N et al.:Identification of a high molecular weight macrophage colony-stimulating factor as a glycosaminoglycan-containing species. J Biol Chem 267:4345-4348, 1992.
17) Price LK, Choi HU, Rosenberg L et al.:The predominant form of secreted colony stimulating factor-1 is a proteogycan. J Biol Chem 267:2190-2199, 1992.
19) Suzu S, Ohtsuki T, Makishima M et al.:Biological activity of a proteoglycan form of macrophage colony stimulating factor and its binding to type V collagen. J Biol Chem 267:16812-16815, 1992.
24) Alollso G, Koegl M, Mazurenko N et al.:Sequence requirements for binding of Src family tyrosine kinases to activated growth factor receptors. J Biol Chem 270:9840-9848, 1995.

2 顆粒球コロニー刺激因子 (G-CSF)

P.34 掲載の参考文献
1) 福谷 久, 小川一誠, 堀越 昇・他:悪性腫瘍化学療法におけるRecombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) の併用効果-phase I Study-. 癌と化学療法 16:2005-2012, 1989.
2) 尾山 淳, 太田和雄, 浅野茂隆・他:非ホジキンリンパ腫に対するRecombinant G-CSF (rG・CSF注) の臨床検討. 日癌治 25:1619-1634, 1990.
3) 小川一誠:ナルトグラスチムnartograstim 新しい治療薬のポイント. Vol 2, メディカルレビュー, 1995, p109-121.
4) 小川一誠, 正岡 徹, 高久史麿:悪性リンパ腫化学療法後の白血球減少に対するKRN 8601 第2相試験. 臨床医薬 6:23-40, 1990.
5) 小川一誠, 溝口秀昭, 外山圭助・他:KW-2228の初期第II相臨床試験. 臨床医薬 7:1973-1987, 1991.
6) 小川一誠, 正岡 徹, 溝口秀昭・他:悪性リンパ腫化学療法後の好中球減少に対するKRN 8601(rhG-CSF) の第III相試験-プラセボを対照とする多施設二重盲検比較試験-. 癌と化学療法 17 (PART 1):365-373, 1990.
7) 尾山 淳, 太田和雄, 浅野茂隆・他:非ホジキンリンパ腫に対するRecombinant Human G・CSF (rG・CSF注) の2重盲検交叉比較試験. 日癌治 25:2533-2548, 1990.
8) 小川一誠, 溝口秀昭, 正岡 徹・他:非ホジキンリンパ腫化学療法時の好中球減少に対するKW-2228の第III相臨床試験-プラセボを対照とする多施設2重盲検比較試験-. Biotherapy 6:95-103, 1992.
10) Green JA, Trillet VN, Manegold C et al.:r-met HUG-CSF (G-CSF) with CDE chemotherapy (CT) in small cell lung cancer:Interim result from a randmized placebo controlled trial. Proc ASCO 10:243, 1991.
11) Mather DW, Lieschke GJ, Green M et al.:Filgrastim in patient with chemotherapy-induced febrile neutropenia. Ann Int Med 121:492-501, 1994.
14) Noda K, Eguchi K, Nakada K et al.:Dose escalation of VM-26 in patients with small cell lung cancer (SCLC). proc ASCO 9:232, 1990.
15) Matsuda N, Fukuoka M, Kusunoki K et al.:Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) plus G-CSF for advanced non-small cell lung cancer (NSCLC). proc ASCO 12:327, 1993.
16) Fujita J, Kamei T, Aviyoshi Y et al.:Dose intensification study of carboplatin (CBDCA) and etoposide (VP16) with G-CSF in smal cell lung cancer (SCLC). proc ASCO 12:331, 1993.
17) Demetri GD, Younger J, McGuire BW et al.:Recombinant methonyl granulocyte-CSF (r-met GCSF) allows an increase in dose intensity of cyclophosphamide/doxorubicin/5-fluorouracil in patients with advanced breast cancer. Proc ASCO 10:70, 1991.
P.42 掲載の参考文献
1) Leevsque J-P, Takamatsu Y, Nilsson SK, Hyalock DN, Simmons PJ:Vascular cell adhesion molecule-1 (CD 106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98:1289-1297, 2001.
2) Becker PS, Wagle M, Matous S, Swanson RS, Pihan G et al.:Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF):occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 3:45-49, 1997.
4) Pitini V, Ciccolo A, Arrigo C, Aloi G, Micali C et al.:Spontaneous rupture of spleen during periferal blood stem cell mobilization in a patient with breast cancer. Haematologica 85:559-560, 2000.
5) 日本造血細胞移植学会:造血細胞移植ガイドライン-移植後早期の感染管理. JSHCT (Japan Society for Hematopoietic Cell Transplantation) monograph vol. 3, 2000.
6) Richman CM, Weiner RS, Yankee RA:Increase in circulating stem cells following chemotherapy in man. Blood 47:1031-1039, 1976.
8) Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W et al:Autologous transplnatation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 67:529-532, 1986.
9) To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P et al.:Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 18:442-447, 1990.
14) 中川 均・他:臨床血液 36:185, 1995.
19) Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T et al.:Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655-1658, 1995.
20) Korbling M, Przepiorka D, Huh Y-O, Engel H, van Besien K et al.:Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma:potential advantage of blood over marrow allografts. Blood 86:2842-2848, 1995.
22) Zeller W, Gutensohn K, Stockschlader M, Dierlamm J, Kroger N et al.:Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. Bone Marrow Transplant 17:709-713, 1996.
23) Kroger N, Renges H, Kruger W, Gutensohn K, Loliger C et al.:A randomized comparison of once versus twice daily recombinant human granulocyte colony stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 111:761-765, 2000.
24) 正岡 徹, 森山美昭, 加藤俊一・他:骨髄移植におけるKRN 8601 (rhG-CSF) の二重盲検比較臨床試験成績. 今日の移植 3:233-239, 1990.
25) 浅野茂隆, 正岡 徹, 高久史麿・他:骨髄移植におけるrecombinant human granulocyte colony-stimulating factor (rG-CSF注) の臨床評価-プラセボを対照とした二重盲検比較試験. 今日の移植 3:317-324, 1990.
26) 加藤俊一, 正岡 徹, 小寺良尚・他:骨髄移植後の好中球減少に対するKW-2228の臨床効果-プラセボを用いた二重盲検比較試験. 今日の移植 5:73-78, 1992.
28) Schmitz N, Dreger P, Zander AR, Ehninger G, Wandt H et al.:Results of a randomized, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoingautologous bone marrow transplantation. Bone MarrowTransplant 15:261-266, 1995.
32) Bishop MR, Stefano R, Tarantolo, Robert B, Geller TRB et al.:A randomized, doubleblind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96:80-85, 2000.
35) Japan Society for Hematopoietic Cell Transplantation:Monograph vol 3, p8-9, 2000.
36) Bensinger WI, Price TH, Dale DC et al.:The effects ofdaily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883-1888, 1993.
37) Caspar CB, Seger RA, Burger J, Gmur J:Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 81:2866-2871, 1993.
39) Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A:Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012-2020, 1992.
P.55 掲載の参考文献
1) 清水宏之, 松下陽子, 青木国雄・他:不応性貧血の全国有病者調査. 厚生省特定疾患特発性造血障害調査研究班 平成3年度研究業績報告書, 1992, p82-83.
2) 高久文麿:厚生省特定疾患特発性造血障害調査研究班 平成2年度研究業績報告書. 再生不良性貧血分科会, 1991, p57-58.
4) Ogawa M:Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844-2853, 1993.
6) Moore MAS:Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78:1-19, 1991.
9) Schrezenmeier H, Jenal M, Herrmann F, Heimpel H, Raghavachar A:Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood 88:4474-4480, 1996.
11) Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JCW et al:Progressive telomere shortening in aplastic anemia. Blood 91:3582-3592, 1998.
12) Holmberg LA, Seidel K, Leisenring W, Torok-Storb B:Aplastic anemia:Analysis of stromal cell function in long-term marrow cultures. Blood 84:3685-3690, 1994.
13) Marsh JCW, Chang J, Testa NG, Hows JM, Dexter TM:The hematopoietic defect in aplastic anemia assessed by long-term marrow culture. Blood 76:1748-1757, 1990.
16) Nakao S, Takamatsu H, Chuhjo T, Ueda M, Shiobara S et al.:Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84:4257-4261, 1994.
17) Nakao S, Takami A, Takamatsu H, Zeng W, Sugimori N et al.:Isolation of a T-cell clone showing HLA-DRB1 * 0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89:3691-3699, 1997.
18) 浅野茂隆, 平嶋邦猛, 吉田弥太郎, 高久文麿, 宮崎 保・他:再生不良性貧血に対するrecombimant human granulocyte colony-stimulating factor の臨床効果. 臨床血液 31:1456-1462, 1990.
19) 小島勢二, 松山孝治, 宮崎 保, 桜田恵右, 沖野栄蔵・他:再生不良性貧血におけるKRN8601. (rh-G- CSF) の臨床効果に関する検討. 臨床血液 31:929-936, 1990.
21) Maciejewski JP, Liu JM, Green SW, Walsh CE, Plumb M et al.:Expression of stem cell inhibitor (SCI) gene in patients with bone marrow failure. Exp Hematol 20:1112-1117, 1992.
23) Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A et al., Ferster A for EBMT working party on SAA and the GITMO:Antilymphocyte globulin, prednisolone, and granulocyte colony-stimulating factor for severe apalastic anemia:an update of the GITMO/EBMT study on 100 patients. Blood 95:1931-1934, 2000.
24) Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, Hann I, Nikiforakis E et al., Bacigalupo A for the EBMT working party on AA:Results of a randamized study of glycosilated rHuG-CSF lemograstim in severe aplastic anemia. Blood 92 (Suppl 1):376a, 1998.
25) Kurzrock R, Paquette R, Gratwohl A:Use of stem cell factor (Stemgen, SCF) and filgrastim (G-CSF) in aplastic anemia patients who have failed ATG/ALG therapy. Blood 90 (Suppl 1):173, 1997.
28) Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S et al.:Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 90:1009-1013, 1997.
30) Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A et al. for the EBMT SAA working party:Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 329:1152-1157, 1993.
31) Locasciulli A, Arcese W, Locatelli F, Bona ED, Bacigalupo A for the Italian aplastic anemia group:Treatment of aplastic anemia witll granulocyte-colony stimulating factor and risk of malignancy. Lancet 357:43-44, 2001.
35) Appelbaum FR, Barrall J, Storb R, Ramberg R, Doney K et al.:Clonal cytogenetic abllormalities in patients with otherwise typical aplastic anemia. Exp Hematol 15:1134-1139, 1987.
37) 溝口秀昭:平成8年度次総括報告. 厚生省血液疾患調査研究班特発性造血障害分科会平成8年度研究業績報告書, 1997, p5-9.
P.63 掲載の参考文献
1) Haeney ML, Golde DW:Myelodysplasia. N Engl J Med 340:1649-1660, 1999.
2) 別所正美:MDSのサイトカイン療法. 血液フロンティア 10:187-193, 2000.
7) Bennett JM:World Health Organization Classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:131-133, 2000.
8) Greenberg P, Cox C, LeBeau MM et al.:International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997; Erratum, Blood 91:1100, 1998.
9) Raza A, Gezer S, Mundle S et al.:Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268-276, 1995.
10) Raza A, Alvi S, Broady-Robinson L et al:Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo-and/or bromodeoxyuridine. Exp Hematol 25:530-535, 1997.
11) Rajapaksa R, Ginzton N, Rott LS et al.:Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275-4287, 1996.
12) Mundle SD, Venugopal P, Cartlidge JD:Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 88:2640-2647, 1996.
13) Ganser A, Seipelt G, Verbeek W et al:Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 8:369-375, 1994.
14) Im T, Yamane T, Muginani A et al.:Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int J Haematol 60:215-223, 1994.
16) Negrin RS, Haeuber DH, Nagler A et al.:Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43, 1990.
17) Greenberg P, Taylor K, Larson R et al.:Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood 82 (Suppl. 1):196a, 1993.
19) Hellstrom-Lindberg E, Birgeard G, Carlsson M et al.:A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromis. Leuk Lymph 11:221-228, 1993.
20) Negrin RS, Stein R, Vardiman J et al.:Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737-743, 1993.
23) Bessho M, Hirashima K, Asano S et al.:Treatment of the anemia of aplastic anemia patients with recombinanthuman erythropoietin in combination with granulocyte colony-stimulating factor:a multicenter randomized controlled study. Eur J Heamatol 58:265-272, 1997.
24) Negrin R, Stein R, Dohety K et al.:Maintenance treatment of the animia of myelodysplastic syndromes with recombinant human erythropoietin. Blood 87:4076-4081, 1996.
25) Hellstrom-Lindberg E, Kanter-Lewensohn, Ost A:Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte CSF and erythropoietin. Leuk Res 21:415-425, 1997.
26) Hellstrom-Lindberg, Negrin R, Stein R et al.:Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes:proposal for a predictive model. Br J Haematol 99:344-351, 1997.
27) Hellstrom-Lindberg E, Ahlgren T, Beguin Y et al.:Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoientin:results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75, 1998.
28) Remacha AF, Arrizabalaga B, Villefas A et al.:Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica 84:1058-1064, 1999.
P.69 掲載の参考文献
6) Koistinen P, Wang C, Curtis JE et al.:Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. Leukemia 5:789-795, 1991.
7) Bettelheim P, Valent P, Andreeff M et al.:Recombinant human granulocyte-macrophage colony stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700-711, 1991.
8) Estey E, Thall PF, Kantarjian H et al.:Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin:comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992.
9) Archimbaud E, Fenaux P, Reiffers J et al.:Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 7:372-377, 1993.
11) Ohno R, Naoe T, Kanamaru A et al:A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83:2086-2092, 1994.
13) Cannistra SA, DiCarlo J, Groshek P et al.:Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 5:230-238, 1991.
14) Heil G, Chadid L, Hoelzer D et al.:GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 9:3-9, 1995.
17) Lowenberg B, Suciu S, Archimbaud E et al.:Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia:final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organizationfor the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90:2952-2961, 1997.
18) Witz F, Sadoun A, Perrin MC et al.:A placebo-controlled study of recombinant human granulocyte macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91:2722-2730, 1998
20) Tafuri A, Lemoli RM, Chen R et al.:Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia 8:749-757, 1994.
P.76 掲載の参考文献
5) Budman DR, Berry DA, Cirrincione CT et al.:Dose and dose intensity as determinants of outocome in the adjuvant treatment of breast cancer. J Natl Cancer Insti 90:1205-1211, 1998.
8) Ottosson S, Magunusson K, Hultborn R:Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery. Anticancer Res 10:4429-4434, 1999.
9) Fergason JE, Dodwell DJ, Seymour AM et al.:High dose, dose-intensity chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. Br J Cancer 67:825-829, 1993.
12) Crawford J, Ozer H, Stoller R et al.:Reduction by granulocyte colony-stimulationg factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991.
13) Trillet-Lenoir V, Green J, Manegold C et al.:Recombinant granulocyte colony stimulating factor reduces the infectious complication of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993.
16) 磯部 威, 福岡正博, 根来俊一・他:限局型小細胞癌に対するDose Intensive Weekly化学療法とCisplatin + Etoposide + 胸部放射線同時照射併用のPilot Study. 癌と化学療法 27:1091-1096, 2000.
18) Fujita A, Takabatake H, Takagi S et al.:Phase I study of carboplatin, docetaxel and irinotecan with recombinant human granulocyte colony stimulating factor supported in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 11:821-824, 2000.
20) 平野正美, 岡本昌隆, 丸山文夫・他:悪性リンパ腫-非交差耐性多薬剤の短期集中交替療法(CAMBO-VIP)を中心に-. 癌と化学療法 17:1982-1988, 1990.
23) 檀 和夫:血液疾患に於けるG-CSFの役割. 臨床血液 38:367-370, 1997.
P.89 掲載の参考文献
1) 臼杵憲祐, 浦部晶夫:炎症感染症治療への応用. 症例に学ぶG-CSFの臨床. (池田康夫・編), 医薬ジャーナル社, 東京, 1999, p169.
3) Ploomaecher T, Korth C, Mullington J et al.:Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 87:900-905, 1996.
4) Paykrt D, Manten A, vander Poll T et al.:Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 90:1415-1424, 1997.
6) Held TK et al:Granulocyte colony-stimulating factor worsens the outcome of experimental Klebsiella pneumoniae pneumonia through direct interaction with the bacteria. Blood 91:2525, 1998.
7) 浦部晶夫:G-CSFと間質性肺炎に関する臨床的検討. 診断と治療 86:99-104, 1998.
8) Wiiliams MS, Strussenberg HJ, Loveless RM et al.:Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 87:919-925, 1996.
10) Bergamini A, Permo CF, Dini L et al:Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding. Blood 84:3405-3412, 1994.
11) Groopman JE, Freder D:Hematopoietic growth factors in AIDS. Semin Oncol 19:408-414, 1992.
12) Nelson S, Daifuku R, Andersen J:Use of filgrastim (r-metHuG-CSF) in infectious diseases. Filgrastim (r-metHuG-CSF) in clinical practice. (eds. Morstyn G, Dexter TM), Marcel Dekker Inc, New York, 1994, p253-263.
13) Smith WS, Sumnicht GE, Sharpe RW et al:Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis:analysis of survival and multisystem organ failure. Blood 86:1301-1309, 1995.
15) The ACCP/SCCM consensus conference committee:Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644, 1992.
16) Weiss M, Moldawer LL, Schneider EM:Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness. in systemic inflammatory response syndrome and sepsis. Blood 93:425, 1999.
22) Voskaridou E et al.:Healing of chronic leg ulcers in the hemogloblinopathies with perilesional injections of granulocyte-macrophage colony-stimulating factor. Blood 93:5368, 1999.
27) Schribler KR, Liechty KW, White WL et al.:Production of granulocyte colony-stimulating factor in vitro by monocytes from preterm and term neonates. Blood 82:2478-2484, 1993.
28) Gilmore WS, McKelvey-Martin VJ, Rutherford S et al.:Human mild contains granulocyte colony stimulating factor. Eur J Clin Nutr 48:222-224, 1994.
29) Gillan ER, Christensen RD, Suen Y et al:A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis:significant induction of peripheral and bone marrow neutrophilia. Blood 84:1427-1433, 1994.
31) Repp RP, Helm G, van de Winkel GJ:Use of filgrastim (r-metHuG-CSF) in autoimmune disease. Filgrastim (r-metHuG-CSF)in clinical practice. 2nd Ed. (eds. Morstyn G, Dexter TM), Marcel Dekker Inc, New York, 1998, p553-573.
34) Klein HG, Strauss RG, Schiffer CA:Granulocyte transfusion therapy. Semin Hematol 33:359-368, 1996.
35) Huebel K, Dale DC, Engert A et al.:Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 183:321-328, 2001.
38) Pan L et al.:Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2cytokine production and reduces severity of experimental graft-versus-host disease. Blood 86:4422, 1995.
39) Pollmaecher T et al.:Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 87:900, 1996.
41) Schiliro GJ et al.:Impairment in gas exchange after granulocyte colony-stimulating factor (G-CSF) in a patient with the adult respiratory distress syndrome. Chest 107:276, 1995.
42) Paykrt D et al.:Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 90:1415, 1997.
50) Besinger WI, Price TH, Dale DC et al.:The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883-1888, 1993.
51) Caspar CB, Seger RA, Burger J et al.:Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 81:2866-2871, 1993.
56) Price TH, Bowden RA, Boeckh M et al.:Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95:3302-3309, 2000.
58) Huebel K, Dale DC, Rodger E, Gaviria JM et al.:Preservation of function in granulocyte concentrates collected from donors stimulated with G-CSF/dexamethasone during storage at reduced temperature. [abstract] Blood 96:820a, 2000.
P.101 掲載の参考文献
7) Lagesse E et al.:Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nature Med 6:1229-1234, 2000.
9) Kawashima I et al.:CD34+ human marrow cells that express low levels of Kit protein are enriched for long-term marrow-engrafting cells Blood 87:4136-4142, 1996.
11) Ebihara Y et al.:Synergistic action of Flt 3 and gp 130 signalings in human hematopoiesis. Blood 90:4363-4368, 1997.
16) Ueda T et al.:Ex vivo expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk 2/Flt 3 ligand, thrombopoietin interleukin-6 and soluble interleukin-6 receptor. J Clin Invest 105:1013-1021, 2000.
17) Bennaceur-Griscelli A at el:Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34+ CD38 low/neg human bone marrow cells. Blood 94:529-538, 1999.
18) 安藤 潔・他:Ex vivo 増幅造血幹細胞による造血再構築. 最新医学 56:246-253, 2001.
19) Xu M et al.:Stimulation of Mouse and Human Primitive Hematopoiesis by Murine Embryonic Aorta-Gonad-Mesonephros-Derived Stromal Cell Lines. Blood 92:2032-2040, 1998.
20) Burgger W et al.:Reconstitution of hematopoiesis after high-dose chemotherapy by autologus progenitor cells generated ex vivo. N Engl J Med 333:283-287, 1995.
22) Stiff P et al.:Autologus transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood 95:2169-2174, 2000.
25) Kurtzberg J:Clinical trials of ex vivo expanded placental cord blood stem cell transplantation. Exp Hematol 29 (supple1):Corporate symposium 2, 2001.
P.109 掲載の参考文献
1) Cavazzana-Calvo M, Hacein-Bey S, Fischer A et al.:Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672, 2000.
2) Takebayashi H, Oida H, Kakizuka A et al.:Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins:novel biological tools for controlling apoptosis in vivo. Cancer Res 56:4164-4170, 1996.
8) Russell DW, Kay MA:Adeno-associated virus vectors and hematology. Blood 94:864-874, 1999.
13) Ito K, Ueda Y, Ozawa K et al.:Development of a novel selective amplifier gene for controllable expansion of transduced hematopoietic cells. Blood 90:3884-3892, 1997.
15) Xu R, Kume A, Ozawa K et al.:A selective amplifier gene for tamoxifen inducible expansion of hematopoietic cells. J Gene Med 1:236-244, 1999.

3 マクロファージコロニー刺激因子 (M-CSF)

P.116 掲載の参考文献
3) Masaoka T:Five-year follow-up of patients in randomized placebo controlled study of macrophage colony stimulating factor for allogeneic bone marrow transplantation. ACOS presentation for pubrication in the Japanese J Cancer Chemotherapy. Jpn J Cancer Chemother 24(Suppl. 1):178-181, 1997.
5) Cohen S B A, Wooley J, Bogunia-Kubik K et al.:Macrophage colony stimulating factor (M-CSF) within cord blood sera may be partially responsible for the reduced proliferation of cord blood T cells. Eur Cytokine Netw 11:608-611, 2000.
6) Nemunaitis J, Shannon-Dorcy K, Appelbaum F et al.:Long term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony stimulating factor. Blood 82:1422-1427, 1993.
P.120 掲載の参考文献
2) Hatake K, et al. (投稿準備中).
3) Takeyama H, Kajiguchi T, Miyata Y, Saito M:In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia. 癌と化学療法 27(6):873-878, 2000.
6) Matsushita K, Matsumoto T, Arima N, Hidaka S, Ohtsubo H, Tanaka H:Successful adjuvant therapy of M-CSF with chemotherapy of two cases of chemotherapy resistant acute promyelocytic leukemia. Rinsho Ketsueki 36 (6):621-626, 1995.
8) Fukuhara T, Miyake T, Maekawa I, Kurosawa M, Suzuki S et al.:Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome:a pilot study. Int J Hematol 71(4):366-371, 2000.
P.124 掲載の参考文献
1) がん統計白書-罹患/死亡/予後-1993. (富永祐民・他・編), 篠原出版, 1993.
4) Dembo AJ, Davy M, Stenwig AE:Prognostic factors in patients with stage I epitherial ovarian cancer. Obstet Gynecol 75:263-273, 1990.
6) Young RC, Walton LA, Ellenberg SS et al.:Adjuvant therapy in stage I and stage II epitherial ovarian cancer:Results of two prospective randomized trials. N Engl J Med 322:1021-1027, 1990.
7) Young RC, Brady MF, Nieberg RM et al.:Randomized clinical trial of adjuvant treatment of women with early (FIGO I-II A, high risk) ovarian cancer:GOG#95. Proceedings of the International Gynecologic Cancer Society, Fukuoka, Japan, 1997.
10) Ochiai K, Terashima Y:Chemotherapy and granulocyte colony stimulating factor in ovarian cancer. Semin Oncol (Suppl):23-28, 1994.
11) Motoyoshi K, Yoshida K, Hatake K et al:Recombinant and native human urinary colony-stimulating factor directly augments granulocytic and granulocyte-macrophage colony-stimulating factor function of human peripheral blood monocytes. Exp Hematol 17:68-71, 1989.
12) 西村治夫, 薬師寺道明, 高橋 威・他:卵巣悪性腫瘍化学療法におけるヒトマクロファージコロニー刺激因子(P-100) の有用性に関する二重盲検群間比較試験. Oncology & Chemotherapy 13:161-169, 1997.
13) Ochiai K, Ohashi Y, Yakushiji M et al.:Relapse-preventing effect of macrophage colony stimulating factor on patients with ovarian cancer. Proc Am Soc Clin Oncol Abstract, 2000, p211.
P.130 掲載の参考文献
3) Suzu S, Yokota H, Yamada M et al.:Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 49:5913-5917, 1989.
4) Saleh MN, Goldman SJ, LoBuglio AF et al.:CD16+ monocytes in patients with cancer:spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 85:2910-2917, 1995.
6) Deryugina EI, Ratnikov BI, Bourdon MA et al:Identification of a growth factor for primary murine stroma as macrophage colony-stimulating factor. Blood 86:2568-2578, 1995.
8) Tanaka-Douzono M, Suzu S, Yamada M et al.:In vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells. J Cell Physiol 178:267-273, 1999.
P.138 掲載の参考文献
1) Duhrsen U, Hossfeld DK:Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol 73:53-70, 1996.
2) Kitagawa M, Saito I, Kuwata T et al.:Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11:2049-2054, 1997.
5) Im T, Yamane T, Mugitani A, Hiyoshi M, Park K et al.:Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int J Hematol 60:215-223, 1994.
6) Gerhartz HH, Marcus R, Delmer A et al.:A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndrome (MDS) with a high risk of developing leukemia. Leukemia 8:16-23, 1994.
10) Fukuhara T, Miyake T, Maekawa I et al.:Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-t, or leukemic phase myelodysplastic syndrome:a pilot study. Int J Hematol 71:366-371, 2000.
11) Hanspal M, Hanspal JS:The association of erythroblasts with macrophages promotes erythroid proliferation and maturation:a 30-kD heparin-binding protein is involved in this contact. Blood 84:3494-3504, 1994.
12) Deryugina EI, Ratnikov BI, Bourdon MA, Gilmore GL, Shadduck RK et al.:Identification of a growth factor for primary murine stroma as macrophage colony stimulating factor. Blood 88:2568-2578, 1995.
13) Tanaka-Douzono M, Suzu S, Yamada M, Misawa E, Wakimoto N et al.:In vivo stimulatory effect of macrophage colony-stimulating factor on the number of stroma-initiating cells. J Cell Physiol 178:267-273, 1999.
14) Suzu S, Yokota H, Yamada M et al.:Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 49:5913-5917, 1989.
20) Nemunitis J, Shannon-Dorcy K, Appelbaum FR et al:Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 82:1422-1427, 1993.
P.142 掲載の参考文献
1) 奥平雅彦:Opportunistic fungous infectionの病理. 日本病理学会誌 74:61-91, 1985.
2) 五島瑳智子:難治細菌感染症の原因菌と抗菌剤感受性. 難治性感染症治療の現状. 1990, p1-12.
3) Bodey GP:Fungal infection and fever of unknown origin in neutropenic patients. Am J Med 80 (Suppl. 5C):112-119, 1986.
4) Haron E, Feld R, Tuffnell P et al.:Hepatic candidiasis:an increasing problem in immunocompromised patients. Am J Med 83:17-26, 1978.
6) Imamura N, Yamada K, Kuramoto A et al.:Successful treatment of fungal sepsis by M-CSF in a patient with Sezary syndrome. Biotherapy 7:1116-1119, 1993.
8) Fantone JC, Ward PA:Role of oxygen drived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J pathol 107:397-418, 1982.
10) Liew FY, Millott S, Parkinson C, Palmer RM:Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144:4794, 1990.
11) 出口昌志:マクロファージからの一酸化窒素産生とサイトカインによる調節. 臨床免疫 26:993-1000, 1994.
12) Lee MT, Warren MK:CSF-1 induced resistance to viral infection in murine macrophages. J Immunol 138:3019-3022, 1987.
14) Tushinki RJ, Oliver IT, Guilbert LJ:Survival of mononuclear phagocytes depends on lineage-specific growth factor. Cell 28:71-81, 1982.
15) Motoyosi K et al.:Purification and some properties of CSF from human urine. Blood 52:1012-1020, 1978.
17) 元吉和夫:化学療法の領域 10:1095-1100, 1994.
18) Ralph P, Sampson-Johannes A:Hematopoietic growth factors in transfusion medicine. Wiley-Liss, New York, 1990, p43-63.
21) Rosenfeld ME, Yla-Herttuala S, LIpton BA:Am J Pathol 140:291-300, 1992.
22) 藤田英之, 増田博俊, 中島常隆:全身性カンジダ症に対する感染防御効果およびマクロファージ機能への作用. 感染症学雑誌 69:60-65, 1995.
23) 藤田英之, 増田博俊, 中島常隆:全身性アスペルギルス症に対する感染防御効果およびマクロファージ機能への作用. 感染症学雑誌 69:582-589, 1996.
24) Nemunaitis J et al.:Long-term follow up of patients with invasive fungal disease who received adjunctive therapy with rhM-CSF. Blood 82:1422-1427, 1993.
25) Ohno R et al:JClin Oncol 15:2954-2965, 1997.
P.149 掲載の参考文献
3) Gronthos S, Simmons P:The growth factor requirements of STRO-1 positive human bone marrow stromal precursors under serum-deprived conditions in vitro. Blood 85:929-940, 1995.
4) Hirata J, Kaneko S, Nishimura J et al.:Effects of platelet-derived growth factor and bone marrow derived fibroblastoid colony-forming cells. Acta Haematol 74:189-194, 1985.
7) Wang Q, Yan Z, Wolf N:Dissecting the hematopoietic microenvironment. VI. The effects of several growth factors on the in vitro growth of murine bone marrow CFU-F. Exp Hematol 18:341-347, 1990.
8) Deryugina E, Ratnikov B, Bourdon M et al:Clonal analysis of primary marrow stroma:functional homogeneity in support of lymphoid and myeloid cell lines and identification of positive and negative requlators. Exp Hematol 22:910-918, 1994.
9) Deryugina E, Ratnikov B, Bourdon M et al.:Identification of a growth factor for primary murine stroma as macrophage colony-stimulating factor. Blood 86:2568-2578, 1995.
11) Tanaka-Douzono M, Suzu S, Yamada M et al.:Detection of murine adult bone marrow stroma-initiating cells in Lin- c-fms+ c-kit low VCAM-1+ cells. J Cell Physiol 2001. (in press)
12) Fibbe W, va Damme J, Billiau A et al.:interleukin-1 induces human marrow stromal cells in longterm culture to produce granulocyte colony-stimulating factor and macrophage colony-stimulating factor. Blood 71:430-435, 1988.
13) Kittler E, McGrath H, Temeles D et al.:Biologic significance of constitutive and subliminal growth factor production by bone marrow stroma. Blood 79:3168-3178, 1992.
14) Nemunaites J, Andrews D, Mochizuki D et al.:Human marrow stromal cell response to interleukin-6 (IL-6) and control of IL-6 expression. Blood 74:1929-1935, 1989.
15) Piersma A, Brockbank K, Ploemacher R:Regulation of in vitro myeropoiesis by hemopoietic stromal fibroblastic cell line. Exp Hematol 12:614-623, 1984.
17) Sieff C, Neimeyer C, Mentzer S et al.:Interleukin-1, tumor necrosis factor, and the production of colony-stimulating factors by cultured mesenchymal cells. Blood 72:1316-1323, 1988.
24) Kimura F, Douzono M, Ohta J et al.:Augmentation of antitumor immunity using genetically M-CSF expressing L1210 cells. Exp Hematol 24:360-363, 1996.
25) Morita T, Ikeda K, Douzono M et al.:Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice. Blood 88:955-961, 1996.
26) Suzu S, Yokota H, Yamada M et al.:Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 49:5913-5917, 1989.
P.158 掲載の参考文献
1) Suzu S, Tokota H, Yamada M et al:Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 49:5913-5917, 1989.
5) Motoyoshi K, Douzono M, Sakurai T et al.:In vitro and in vivo antitumor activities of monocytes potentiated by macrophage colony-stimulating factor. Gann Monograph on cancer Research 40:75-80, 1993.
11) Ochiai K, Ohashi Y, Yakushiji M et al.:Relapse-preventing effect of macrophage colony-stimulating factor on patients with ovalian cancer. Proceedings of ASCO 19:55a, 2000.
12) 正岡 徹:同種骨髄移植におけるM-CSFのランダム化二重盲検比較試験の5年生存率. Biotherapy 13:881-885, 1999.
13) 元吉和夫, 宮脇修一, 畠 清彦・他:M-CSF臨床応用の将来展望. 臨床血液 38:375-379, 1997.
P.164 掲載の参考文献
9) 保田尚孝, 後藤雅昭:破骨細胞形成抑制因子 (Osteoclastogenesis inhibitory factor, OCIF)と破骨細胞分化因子 (Osteoclast differentiation factor, ODF):破骨細胞の分化・成熟を調節するメカニズム. 日本骨代謝学会雑誌 17:10-18, 1999.
12) Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW et al.:Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J Exp Med 156:1516-1527, 1982.
13) Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW et al.:Total absence of colony-stimulating factor 1 in the macrophage deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87:4828-4832, 1990.
22) Jimi E, Shuto T, Koga T:Macrophage colony-stimulating factor and interleukin-1α maintain the survival of osteoclast-like cells. Endocrinology 136:808-811, 1995.
23) Felix R, Cecchini MG, Fleisch H:Macrophage colony stimulating factor restores in vivo bone resorption inthe op/op osteopetrotic mouse. Endocrinology 127:2592-2594, 1990.
24) Sarma U, Edward M, Motoyoshi K et al.:Inhibition of bone resorption by 17 β-estradiol in human bone marrow cultures. J Cell Physiol 175:99-108, 1998.
30) Murakami T, Yamamoto M, Yamamoto M et al:Transforming growth factor-β 1 increases mRNA levels of osteoclastogenesis inhibilory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252:747-752, 1998.
47) Iotsova V, Caamano J, Loy J et al.:Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Medicine 3:1285-1289, 1997.
49) Takayanagi H, Ogasawara K, Hida S et al.:T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature 408:600-605, 2000.
P.173 掲載の参考文献
1) Medawar PB:Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. In Society for Experimental Biology. Vol. 7. Academic Press, New York, 1953, p320-338.
6) Silen ML et al.:Interleukin-1α and tumor necrosis factor-α cause placental injury in the rat. Am J pathol 135:239-244, 1989.
11) Fehsel K et al.:Nitric oxide induces apoptosis in mouse thymocytes. J Inmmuno1 155:2858-2865, 1995.
14) Saito S et al.:High serum human macrophage colony stimulating factor level during Pregnancy. Int J Hematol 55:219-225, 1992.
20) Katano K et al.:Clinical trial of immunostimulation with a biological response modifier in unexplained recurrent spontaneous abortion patients. J Clin Immunol 17:472-477, 1997.
P.181 掲載の参考文献
2) Munn DH, Garnick MB, Cheung NK:Effects of parenteral recombinant human macrophage colony-stimulating factor on monocyte number, phenotype, and antitumor cytotoxicity in nonhuman primates. Blood 75:2042-2048, 1990.
4) Suzu S, Yokota H, Yamada M et al.:Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 49:5913-5917, 1989.
13) Morita T, Ikeda K, Douzono M et al.:Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice. Blood 88:955-961, 1996.
15) Kimura F, Douzono M, Ohta J et al.:Augmentation of antitumor immunity using genetically M-CSF-expressing L1210 cells. Exp Hematol 24:360-363, 1996.
19) Graf MR, Jadus MR, Hiserodt JC et al.:Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor. J Immunol 163:5544-5551, 1999.
P.187 掲載の参考文献
4) Hidaka T, Fujimura M, Saito S et al:Macrophage Colony-stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy. Jpn J Cancer Res, (in press).
5) Hubel K, Hegener K, Schnell R et al.:Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 78:73-77, 1999.
7) Teranishi A, Akada S, Saito S, Morikawa H:Restored chemotherapy-induced granulocyte dysfunction by macrophage colony-stimulating factor via secondary IL-8 production by monocytes. Int. J. Immunopharmaco, (in press).
8) 寺西明子, 斎藤 滋, 森川 肇・他:卵巣癌化学療法後の好中球接着分子の変動に関する研究- M-CSF投与の有無による比較検討-Oncology & Chemotherapy, 13:231-236, 1997.
12) Phillip N, Jacobs S, Stoller R et al.:Effect of recombinant human granulocyte macrophage colony-stimulating factor on myelopoiesis in patients with refractory metastatic carcinoma. Blood 74:26-34, 1989.
14) Carlos TM, Harlan LM:Leukocyte-endothelial adhesion molecules. Blood 84:2068-2101, 1994.
15) Hashimoto S, Yoda M, Yamada M et al:Macrophage colony-stimulating factor induces interleukin-8 production in human monocytes. Exp Hematol 24:123-128, 1996.

最近チェックした商品履歴

Loading...